Lynparza Improves Survival in BRCA-Mutated Recurrent Ovarian Cancer

SOLO-2 Trial: Lynparza Improves Progression-Free Survival in BRCA-Mutated Platinum Sensitive Recurrent Ovarian Cancer

Lynparza Improves Survival in BRCA-Mutated Recurrent Ovarian Cancer

by Dr. C.H. Weaver M.D. updated 10/2018

Results were recently presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in National Harbor, USA, demonstrating that Lynparza (olaparib) reduced the risk of platinum-sensitive, relapsed ovarian cancer patient’s progression by 70%.1

About SOLO-2 Clinical Trial

SOLO-2 was a clinical trial designed to determine the effectiveness of Lynparza tablets as a maintenance therapy compared with placebo, in patients with platinum-sensitive relapsed or recurrent gBRCA-mutated (BRCAm) ovarian cancer. Overall 295 patients with documented germline BRCA1 or BRCA2 mutations who had received at least 2 prior lines of platinum-based chemotherapy and were in complete or partial response were enrolled to be treated with Lynparza or placebo and were directly compared.

About Lynparza

LynparzaTM constitutes the first PARP inhibitor approved for treating ovarian cancer. Lynparza was approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment.1,2

The PARP enzyme plays a role in DNA repair, including the repair of DNA damage from chemotherapy. Drugs that inhibit this enzyme may contribute to cancer cell death and increased sensitivity to chemotherapy. PARP inhibitors are thought to have the greatest effect in women with mutations of the BRCA genes, who represent about 15% of ovarian-cancer patients. But recent research, still ongoing, indicates that the drugs may benefit an additional 35% of patients with different genetic profiles.

The current clinical trial showed an improvement with Lynpara maintenance: the time Lynparza treated patients survived without cancer progression was 30.2 months compared to only 5.5 months for placebo treated patients. Eric Pujade-Lauraine, Head of the Women Cancers and Clinical Research Department at Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, and Principal Investigator of the trial said: “Today’s results are very encouraging, as they build upon previous trials examining Lynparza in platinum-sensitive relapsed BRCA-mutated ovarian cancer. Most importantly, patients were able to maintain quality of life while experiencing an impressive delay in disease progression, demonstrating the benefits of Lynparza tablets for these women whose cancer is often difficult to treat.”


  1. Pujade-Lauraine, J.A., et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study. In: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 12 – 15, 2017; National Harbor, MD, USA.

Copyright © 2018 CancerConnect. All Rights Reserved.